



Poster Exhibition

ID	Title	Presenting Author
Ageing		
139	Ageing in HIV from a gender perspective: results from a survey assessing needs and provisions of care	Luisa Brogonzoli, Milano
187	Attitudes toward aging and HIV-related stigma in elderly people with HIV	Samuele Gardin, Padova
130	The Glasgow Manifesto in Italy: A platform for change	Nicoletta Policek, Bruxelles
Basic Science - Immunology		
224	Elevated levels of interleukin-15 in naïve PLWH normalize earlier for those treated in the primary phase of infection	Giorgio Bozzi, Milano
274	Evaluation of T cell-mediated immune response after dengue infection: a comparison between people living with HIV and HIV-negative individuals	Pierluigi Francesco Salvo, Roma
98	Immunomodulatory effects of HIV Tat's N-terminal sequence on CD8+ T cells	Enrico Tassani, Ferrara
270	The opposite trend of neurotrophins NGF and BDNF during HIV pathogenesis	Luca Maddaloni, Roma
Clinical HIV (toxicity, comorbidities)		
137	Anal cancer screening in Italy: a pilot survey	Maria Gabriella Dona, Roma
25	Anal cancer screening uptake in a cohort of women with HIV	Maria Mazzitelli, Padova
310	Bempedoic Acid and Evolocumab in People Living with HIV: A Real-World Strategy for Achieving LDL Targets in Statin-Intolerant or Reluctant Patients	Marianna Menozzi, Modena
170	Beyond viral suppression: navigating the polypharmacy maze in elderly people with HIV on antiretroviral therapy	Claudia Gioè, Palermo
277	Cardiovascular management in PLWH: poor adherence to blood pressure and LDL-C targets	Francesca Chiappini, Chieti
197	CAROTID AND FEMORAL INTIMA MEDIA THICKNESS (C-IMT AND F-IMT): RISK STRATIFICATION FOR CARDIOVASCULAR EVENTS IN PLWH	Giovanbattista Martone, Caserta
49	CHALLENGING RETENTION IN CARE IN HIV-VERTICALLY ACQUIRED PEOPLE: A REAL LIFE EXPERIENCE	Anna D'Angelillo, Roma
3	Changes in bone mineral density and bone turnover markers in antiretroviral therapy-naïve people with HIV starting bictegravir/emtricitabine/tenofovir alafenamide or doravirine/lamivudine/tenofovir disoproxil fumarate	Leonardo Calza, Bologna
9	Changes in glucose homeostasis in people living with HIV naïve to antiretroviral therapy and starting dolutegravir/lamivudine or bictegravir/emtricitabine/tenofovir alafenamide	Leonardo Calza, Bologna
337	Changes in lipid profile and cardiovascular risk after switching to long-acting cabotegravir/rilpivirine	Anna Carraro, Roma
289	Comorbidities predict longitudinal cognitive changes in People with HIV	Elisa Vuaran, Torino
203	Correlation between lipid profile, subclinical atherosclerosis and hepatic fibrosteatosis in PLWH: comparison between TAF/FTC/BIC and TDF/3TC/DOR	Ilaria Capriglione, Napoli
285	Disparities in cardiovascular risk management for PLWH: a comparison of ESC and EACS guidelines	Francesca Chiappini, Chieti
120	Evolution of liver fibrosis in a cohort of people living with HIV without active hepatitis co-infections	Manuel Crispo, Siena
33	Glucose homeostasis in People Living With HIV starting long-acting antiretroviral therapy	Alberto Zuppiroli, Bologna
318	HIV & MASLD burden: longitudinal changes, predictive factors and prognostic impact in people living with HIV from Southern Italy.	Antonio Iuliano, Salerno



Poster Exhibition

ID	Title	Presenting Author
215	HIV indicator conditions prior to late presentation: a ten-year analysis in a major clinical center—implications for addressing missed opportunities in one of Italy's top five most affected cities	Gian Carlo Orofino, Torino
329	HIV Still Hiding in Reservoirs: Four Cases of Symptomatic CSF Escape with Tenofovir Alafenamide/Emtricitabine/Bictegravir	Carola Lipani, Torino
216	Implementation of Statin Therapy in an HIV-Positive Cohort: Real-World Challenges and Insights from the REPRIEVE Trial	Chiara Muscatiello, Foggia
324	Lost to follow-up: what's happened? A single center analysis	Chiara Grillo, Foggia
156	Management of pregnancy in women living with HIV: a two-week neonatal prophylaxis and breastfeeding experience	Daniela Piacentini, Belluno
200	Mental health in PLWH: psychopathological variables and personality traits in patients compared with non-clinical subjects in Italy	Francesco Romano, Roma
191	Metabolic impact of switching TAF/FTC/RPV to BIC/TAF/FTC in a real-life setting	Layla Pagnucco, Pavia
264	MULTIdimensional Scale for the Detection of Health Needs in People with HIV: Preliminary Results From the MUSA study	Andrea Calcagno, Torino
173	Predictors of Hospitalization in HIV Patients: Identifying Key Risk Factors	Livia Moffa, Chieti
290	Prevalence and predictors of increased creatine phosphokinase (CPK) levels in a cohort of People Living With HIV (PLWH) treated with modern antiretroviral regimens	Margherita Sambo, Siena
251	Prevalence, predictors and outcomes of poor immunological recovery in PLWH on effective c-ART: a retrospective study from a tertiary University center in Italy.	Marina Sarno, Campobasso
111	Previous COBI-including regimen is the major determinant of lipid profile modification in a cohort of PWH on stable TAF treatment switching to dual treatment.	Nicola Squillace, Monza
228	Re-CALL, Re-TURN, Re-stART: a clinical project for retention in HIV care	Benedetta Trentacapilli, Milano
231	Screening with GAD-2 in a real-life outpatient setting in Milan. High prevalence of anxiety, associated factors and acceptance of psychologic assessment	Andrea Pastena, Milano
145	Statin use in people living with HIV without apparent cardiovascular risk factors: observational study of an outpatient cohort	Veronica D'Aquila, Roma
294	Temporal trends, clinical correlates and prognostic potential of advanced disease in naïve PLWH and impact of COVID-19 pandemic: preliminary results of a 20-year retrospective cohort study	Emanuela Zappulo, Napoli
101	The role of inflammatory and atherogenic markers in a group of young men living with HIV with erectile dysfunction: a cross-sectional study.	Federico Cesanelli, Brescia
307	Transgender people with HIV: challenges in the ART management	Patrizia Pasculli, Roma
Epidemiology		
69	A walk on the wild side: an observational retrospective single center study on a cohort of Trans* women coming from Latin America accessing clinics for HIV and STIs in a teaching hospital in Rome	Anastasia Destro, Roma
112	An HIV Clinic in Bouar, Central African Republic: the cure moves where medical care is missing.	Martina Strano, Milano
113	Antiretroviral therapy in pregnant women living with HIV: real-life data from a tertiary center catering to the greater Milan area, 2019-2025	Margherita Pernich, Milano
201	Association of neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, and platelet-to-lymphocyte ratio values with mortality and the occurrence of non-AIDS and AIDS events	Vincenzo Spagnuolo, Milano
164	Characteristics and clinical outcomes of individuals with HIV and late diagnosis in a healthcare setting in eastern Sicily over the past 15 years	Benedetto Maurizio Celesia, Catania

Poster Exhibition

ID	Title	Presenting Author
180	Clinical characteristics and molecular dynamics of Dengue Cases occurring in Liguria in 2024	Giada Garzillo, Genova
238	Cluster of primary HIV infections sustained by CRF02_AG in intravenous drug users in Milan	Giorgio Bozzi, Milano
181	Co-circulation and co-infection with different influenza viruses in the 2024-2025 FLU season	Giada Garzillo, Genova
295	CORRELATION OF SELF-TEST FOR HIV BOUGHT BY PHARMACIES AND REGIONAL INCIDENCE OF HIV IN ITALY: 2018-2023	Sara Leone, Roma
117	Drug resistance mutations among ART-naïve individuals in Lecco	Federico Conti, Lecco
192	Epidemiology of Enteroviruses in Liguria: Analysis of Data from January 2024 to February 2025	Giulia Guarona, Genova
242	Expanding HCV screening in hospitalized patients: preliminary data of a single centre experience in Monza, Italy	Giulia Ghilardi, Monza
26	HIV infection in migrants from Sub-Saharan Africa in the North East of Italy	Anna Ferrari, Padova
35	HIV testing in Italy: preliminary data from three pilot regions of the PRONTI study, 2018 -2023	Francesca Centrone, Bari
24	Interventions to support breastfeeding among mothers living with HIV: a systematic review and meta-analysis	Francesco Di Gennaro, Bari
271	Investigation on the Continuum of Care in people who inject drug in Italy: the Italian NGOs contribution.	Sara Leone, Roma
67	Low adherence to Post-Exposure Prophylaxis for HIV in people who underwent sexual assault: implementation of a re-call strategy	Arianna Liparoti, Milano
190	Measles Outbreak in Liguria: Molecular Surveillance and Transmission Dynamics in 2024 -2025	Chiada Fraccalvieri , Genova
53	Near full-length sequencing is able to ensure a more accurate HIV-1 subtyping: comparison with commonly used methods	Flavia Smoquina, Roma
245	Occupational and sexual exposures: analysis of post-exposure prophylaxis (PEP) prescription and surveillance program in a large hospital, Northern Italy	Stefania Arsuffi, Brescia
284	Prevalence and incidence trends of AIDS events in people newly diagnosed with HIV infection before and after COVID-19 pandemic: experience from the Pisan cohort	Mario Cesaretti, Pisa
91	Respiratory pathogen profile and its association with hospitalization risk in paediatric patients with acute respiratory infection (ARI): Inpatient and outpatient comparison	Rossana Scutari, Roma
266	Testing for HIV and other sexual transmitted diseases offered in the context of community based voluntary counselling and testing services in the last years in Italy (2019-2023)	Alessandro Caioli, Roma
Hepatitis and Liver Diseases		
214	A model of screening and cascade of care for chronic viral hepatitis in asylum seekers and refugees in Rome	Giulia Quartini, Terni
163	Bulevirtide treatment in people living with HIV/HBV/HDV coinfection	Cecilia Giuliani, Pavia
259	Characterization of a cohort of liver transplant patients for HBV and/or HBV/HDV related complications: results of a Campania multicenter study	Lorenzo Salmoni, Napoli
225	Clinical and instrumental changes of liver function after one year of bulevirtide treatment in Chronic Hepatitis Delta with advanced hepatic disease: insight from a Monocentric Cohort study	Alberto Zuppiroli, Bologna
19	Clinical and virological features of chronic HBV infected patients with genotype E	Maria Alberti, Brescia
2	Comparative investigation on the implementation of the national screening program for HCV in italian regions	Massimiliano Conforti, Torino

Poster Exhibition

ID	Title	Presenting Author
147	Evaluating integrated healthcare pathways for HCV elimination: a pilot study from a large Italian region	Erica De Vita, Pisa
252	Experience from a single centre on HBV seroconversion in people living with HIV and HBV: the relevance of individual clinical history and careful monitoring of viral markers	Marianna Menozzi, Modena
118	Long-term outcomes and incidence of clinically significant events after HCV eradication in people with HIV: data from ICONA/HepaICONA cohorts	Maria Mazzitelli, Padova
143	Optimizing hepatitis C treatment: the impact of patient reported measures in varied healthcare settings in a large Italian region	Erica De Vita, Pisa
144	Quantification of plasma HDV RNA in untreated and Bulevirtide-treated patients with CHD: a comparison between Robogene 2.0, Eurobioplex ebx071 and Altostar	Sara Uceda Renteria, Milano
182	The substantial burden of HDV chronic infection and the gaps in HDV screening across Europe rise the need to implement HDV diagnostics at pan-European level	Ilaria Grossi, Roma
195	Treatment of chronic HDV hepatitis with bulevirtide: preliminary results of a behavior-driven investigation on patients and clinicians	Lorenzo Badia, Bologna
331	Trends in the prevalence and epidemiological characteristics of HDV infection in HBsAg+ persons with or without HIV in Italy: is HIV still a key factor for HDV co-infection?	Massimo Puoti, Milano
220	Unexpected HBV reactivation following discontinuation of antiviral prophylaxis in immunosuppressed subjects with previous HBV exposure	Alessandro Soria, Monza
142	Utility of the Fibrosis-4 Index for 10-Year Risk of All-Cause Mortality in People with HIV: A Retrospective Longitudinal Cohort Study	Costanza Bertoni, Milano
HIV: Antiretroviral therapy		
168	Acceptance rate and reasons for rejection of long-acting injectable CAB/RPV in an Italian center	Alessandra Vergori, Roma
38	Antiretroviral therapy in patients with swallowing disorders: an open issue	Norma Spalletta, Roma
332	B/F/TAF as a switch therapy in a cohort of women living with HIV: a 24-months observational study on durability, effectiveness and metabolic profile	Raffaella Marocco, Latina
92	Bictegravir/tenofovir alafenamide/emtricitabine: a real-life experience in Women Living With HIV (WLWH)	Anna Gidari, Terni
66	Causes of discontinuation of co-formulated DOR/TDF/3TC in ART-experienced adults with HIV-1 after three years of follow-up: Real-world data from a single center in Florence, Italy.	Giuseppe Formica, Firenze
268	Changes in body weight in people living with HIV switching therapy from TAF/FTC/RPV to TAF/FTC/BIC	Rebecca Jo Steiner, Roma
45	Dual versus triple as optimization antiretroviral therapy in people with HIV with stable virological suppression: long-term effectiveness from the MOSAICO Study	Giacomo Berti, Padova
306	Effectiveness and durability of simplification strategies with oral dolutegravir/lamivudine vs long-acting injectable cabotegravir/rilpivirine in virologically suppressed people living with HIV	Andrea Carbone, Roma
243	Immunovirological efficacy of long-acting cabotegravir/rilpivirine therapy and perception of well-being in people living with HIV. Experience of the Infectious Diseases Clinic of Perugia	Elisabetta Schiaroli, Perugia
239	Impact of 2 drug antiretroviral regimens on immune recovery	Rebecca Jo Steiner, Roma
227	Impact of baseline plasma HIV-1 RNA and viral subtype on the achievement of virological suppression in PWH treated with bictegravir/emtricitabine/tenofovir alafenamide in clinical practice	Lorenzo Crupi, Genova
308	Implementation of a same-day ART start model in a real-life setting: experiences from a clinical centre in Italy	Giulia Micheli, Roma

Poster Exhibition

ID	Title	Presenting Author
149	Lipid profile improvement among ART-experienced PLWH switching to Bictegravir/Emtricitabine/Tenofovir alafenamide according to prior INSTI exposure and latest ART regimen	Nicola Colavito, Bari
56	Long-acting injectable antiretroviral therapy (LAI-ART) with cabotegravir (CAB) and rilpivirine (RPV) for the treatment of HIV infection: analysis nearly two years implementation in a university hospital	Francesca Saveria Soave, Parma
76	Metabolic and Immunological Outcomes After Switching to Long-Acting Cabotegravir + Rilpivirine: A 44-Week Multicenter Observational Study (LAHIV)	Filippo Lagi, Firenze
97	Minor revision: simplification therapy with dolutegravir, a retrospective observational study with 96 weeks follow-up	Anita Pupo, Roma
275	Next Generation Sequencing (NGS) of proviral HIV DNA and analysis of APOBEC-induced mutations to assess suitability for long-acting cabotegravir/rilpivirine therapy	Giovanni Massobrio, Genova
249	Patient-reported outcomes in HIV: a study on quality of life in PLWH on long-acting antiretroviral therapy	Antonio Auricchio, Campobasso
212	Proximity-based long-acting therapy: a real-world model at a clinical center for HIV/AIDS care in Turin	Gian Carlo Orofino, Torino
309	Real-life use of bictegravir/TAF/emtricitabine in a cohort of people with HIV with more than 50 years old	Giulia Moi, Sassari
322	Real-World Durability, Safety, and Changes in Lipid and Body Weight Profiles with B/F/TAF in ART- Naive Adults: A 24-Month Observational Study	Giulia Mancarella, Latina
166	Sculpting long-term success in hiv therapy: the synergistic dynamics of dolutegravir and doravirine in a precision-driven dual regimen	Federica Zimmerhofer, Palermo
267	Switching boosted protease inhibitor-based antiretroviral therapy to fostemsavir plus an optimized background in people with HIV with limited therapeutic options: a case series from the FOST SWITCH Study	Andrea Calcagno, Torino
218	Switching from 3 or 2-drug oral regimen to Long-Acting Cabotegravir and Rilpivirine in People With HIV: Real-World Experience from ASST Lecco	Martina Bottanelli, Lecco
177	Treatment interruption among PWH on long-acting-injectable (LAI) Cabotegravir/Rilpivirine: Experience from an Italian HIV Outpatient clinic	Gloria Sangaletti, Pavia
205	Up to half of geriatric people living with HIV are treated with 2-drug INSTI-based regimens	Diego Ripamonti, Bergamo
89	Use of prolonged-release injectable CAB/RPV in outpatients	Nicoletta Bobbio, Genova
122	Virological failures in a real-world cohort: a retrospective analysis of population characteristics and resistance mutations	Claudio Rigamonti, Bologna
Infections in the Immunocompromised Host (viruses including SARS-CoV-2, Bacteria and Fungi)		
253	Circulating autoantibodies targeting G-protein-coupled neurotransmitter receptors: reliable biomarkers for Long COVID diagnosis?	Marta Camici, Rome
171	Early management of COVID-19 infection in solid organ transplant recipients: our experience with antiviral treatments.	Federica Guida Marascia, Palermo
288	Long COVID: looking for a definition	Viola Cogliandro, Monza
125	Long-term neurological outcome in Progressive Multifocal Leukoencephalopathy survivors	María del Carmen García Martearena, Milano
240	Non-tuberculous mycobacteria (NTM) in people with HIV (PWH) in recent cART era: clinical presentation and mortality.	Flavia Sanmartin, Roma
291	Prolonged clinical monitoring of cognitive performance and psychiatric symptoms among PACS	Giulia Del Duca, Roma



Poster Exhibition

ID	Title	Presenting Author
94	SARS-CoV-2 infection in hospitalized oncohematological patients: a comparison between two years	Francesco Izzo, Roma
281	Specific T-cell response to CMV, EBV and VZV in people with multiple sclerosis under disease-modifying therapies	Federica Dominelli, Roma
296	Trajectories and Predictors of Post-COVID-19 Condition Persistence: a prospective evaluation in the EuCARE Study	Andrea Santoro, Milano
74	Unraveling the role of peripheral and mucosal SARS-CoV-2-specific CD8 T cell responses in shaping disease severity	Elena Adelina Gabor, Parma
172	Varicella Zoster Virus Vaccination in patients with haematological diseases and primary immunodeficiencies. Assessment of specific T and B-cell responses	Luigi Coppola, Roma
141	Viral respiratory infections in immunocompromised and immunocompetent patients: a case-control study	Martina Mastropalo, Roma
162	What remains of Long COVID after four years from hospitalization for severe COVID pneumonia	Viola Cogliandro, Monza
Social Science, PROs		
283	Acceptability and availability to change care for people living with HIV followed by home care assistance (HCA)	Valentina Iannone, Roma
6	Analysis of the final data and future prospects of the "FRAGIL/mind" project	Angela Calluso, Bari
246	Anlaids community-based HIV screening as a tool to improve HIV diagnosis among asymptomatic individuals	Rosario Galipò, Roma
14	Anlaids Forum challenges Artificial Intelligence: can algorithms act as a counsellor?	Alberto Venturelli, Roma
11	Assessing awareness of HIV and prevention strategies: a cross-sectional study from two free rapid testing events in Rome	Luca Bortolani, Roma
175	Challenges on Recruiting for the HIV-CORE 007 Cure Trial: the perspective of Infectious Disease Doctors	Elena Bruzzesi, Milano
210	Degree of appropriateness and organization of services dedicated to the administration of CAB+RPV: PWH opinions from an Italian multicenter cohort	Giuseppe Cucinotta, Roma
303	Degree of current knowledge and awareness regarding long-acting injectable antiretroviral therapy in people living with HIV who are undergoing oral therapy	Valentina Iannone, Roma
1	Evolution of HIV Testing Access in the MSM Community: a Comparison of the 2005/2015 and 2015/2025 Decades with a Focus on the Use of the INSTI Test in Meeting Places (Outreach)	Matteo Corda, Milano
129	Exploring the attitude about using telehealth in persons on Pre-Exposure Prophylaxis (PrEP)	Lolita Sasset, Padova
138	From screening to care: Strengthening linkage to services for marginalized populations in Genoa, Italy	Gloria Notore, Genova
87	Getting to the first 95: introducing recommended best practices in national HIV testing guidelines	Paolo Russo, Milano
21	HIV and STI testing beyond key populations: Brescia's first community-based experience	Marco Stizioli, Brescia
248	Increase PrEP uptake to reduce HIV incidence in Italy: the case for simplified PrEP delivery	Pietro Leone Giovanni Vinti, Milano
10	LILA's virtual help desk: giving voice and empowering people with HIV through remote support	Giacomo Dessi, Cagliari
219	MULTIFACTORIAL VULNERABILITY AND HIV: Local response to health-care needs of key populations	Marco Falaguasta, Padova

Poster Exhibition

ID	Title	Presenting Author
64	New challenges in the long-term management of people living with HIV (PLWH): introduction of Patient-Reported Outcomes (PROs) into routine clinical practice. A pilot study	Daniela Segala, Ferrara
250	Patient-reported outcomes (PROs) in people living with HIV treated with long-acting injectable antiretroviral therapy (LAI-ART)	Stefano Rapino, Brescia
77	People living with HIV in treatment with long-acting therapy: what changes in terms of stigma?	Annunziata Romeo, Torino
13	PrEP is an obstacle race	Brunella Mocci, Cagliari
196	Promoting health through movement: fit-walking as an intervention to reduce cardiovascular and metabolic risk in people living with HIV/AIDS in Turin	Gian Carlo Orofino, Torino
301	Psychological outcomes and learning loss in students after the COVID-19 pandemic: findings from EuCARE's SCHOOL studies	Francesca Incardona, Roma
135	School intervention for STIs prevention 2024-2025	Paolo Marco Testoni, Milano
193	Sexualized drug use and chemsex: exploring the link between addiction, sexual risk, and psychological well-being among MSM in Modena, Italy	Gianluca Cuomo, Modena
140	Streethaart project : art as a tool to challenge Stigma and promote well-being among people living with HIV	Carlo Oneto, Napoli
342	The impact of awareness-raising and screening initiatives on the migrant population living in Bergamo	Ilaria Mercurio , Bergamo
30	The role of Ancona Checkpoint in counseling and facilitating PrEP access through tele-visits	Sara Caucci, Ancona
328	Therapeutical group for chemsex addiction	Giorgia Fracca, Milano
STIs		
297	Assessment and monitoring of psychological, sexual, and relational status in individuals accessing a Pre-Exposure Prophylaxis (PrEP) program	Giulia Del Duca, Roma
136	Beyond a standalone checkpoint: Three years of collaboration and growth at IOC'ENTRO, Genoa, Italy	Allegra Ferrari, Genova
325	Bridging gaps in HIV care: an outreach screening program for street-based sex workers	Alessandro Soria, Monza
334	Comparison of STI burden and its predictors in people diagnosed with mpox or vaccinated with MVA-BN	Alessandro Giacinta, Roma
302	Doxycycline vs Penicillin for Late Latent Syphilis: Comparative Analysis of Efficacy data	Damiano Farinacci, Roma
86	Dynamics of syphilis among HIV+: prevalence, incidence and serological results in 1669 PLWH, 2021-23, "D. Cotugno" hospital, Naples	Francesco Maria Fusco, Napoli
299	Dynamics of vaccine-preventable anal HPV genotypes in individuals screened for HPV: a retrospective observational study	Alberto Rizzo, Milano
90	HIV PrEP and STI Surveillance: insights from a Tertiary HIV Unit	Francesco Barbaro, Padova
333	HPV and STIs screening in outpatient clinic. The multidisciplinary experience in AOUP- Pisa (preliminary data)	Laura Del Bono, Pisa
28	Impact of genotypic substitutions on treatment failure for Mycoplasma genitalium infection	Nicholas Brian Bana, Milano
18	Implementation of PrEP in Italy: Highlights and Challenges. Findings from the PrIDE Survey	Silvia Nozza, Milano
124	Investigation of Additional Risk Factors to Prioritize Anal Cancer Screening in MSM Living With HIV	Eugenio Nelson Cavallari, Roma
258	More Testing, More STDs? The paradox of follow-up in people on PrEP	Damiano Farinacci, Roma



Poster Exhibition

ID	Title	Presenting Author
127	Outcomes of Anal High Grade Dysplasia Treatment in MSM living with HIV and MSM living without HIV	Eugenio Nelson Cavallari, Roma
104	PrEP—Where are we now? Understanding providers' perspectives on current practices and long-acting PrEP in Southern Italy	Mariacristina Polisenio, Bari
55	Prevalence of syphilis among people living with HIV (PLWH), pre-exposure prophylaxis (PrEP) users and individuals screened for sexually transmitted disease (STD) attending Ferrara HIV/AIDS Section. A comparative observational study.	Daniela Segala, Ferrara
222	Scabies: not just a neglected disease, but a public health concern among key populations	Giulia Lenzi, Roma
48	Sexually transmitted infections, condom use and sexual behaviors in women: the WomanIST experience in an Italian reference center	Giada Canavesi, Legnano
16	The need and frequency of STI testing depends on the lifestyle of the people on PrEP. Data from the PrEP Point Plus (PPP) in Bologna	Sandro Mattioli, Bologna
Vaccines		
188	A Rapid Fluorometric Approach for Evaluating ADCC Activity Against Different forms of HIV -1 Env Protein	Mara Martino, Ferrara
206	Current adherence and vaccine hesitancy to Herpes Zoster vaccination in northern Italy: a cumulative trend analysis at an HIV clinical center in Turin	Gian Carlo Orofino, Torino
44	Evaluating the long-term antibody response of MVA-BN in people living with HIV (PLWH): a two-year monocentric follow-up study	Pierluigi Francesco Salvo, Roma
43	Evaluation of virologic rebounds in people living with HIV (PLWH) after receiving MVA-BN vaccination for mpox	Pierluigi Francesco Salvo, Roma
323	Hepatitis B vaccine response in people living with HIV and with isolated anti-HBc serological profile: a retrospective study	Emanuele Guarise, Genova
236	Multi-cytokine assessment of T-cell responses to Varicella Zoster Virus glycoprotein E after vaccination with a recombinant adjuvanted subunit vaccine in patients with multiple sclerosis on immune modulating treatments	Livia Benedetti, Roma
237	The impact of vaccination on presentation and clinical outcomes in patients hospitalized for COVID-19 Pneumonia in a Lombardy Tertiary Care Center	Nicole Gemignani, Lecco
Virology and Pharmacology		
208	Evaluation of AD4SEQ HIV-1 Whole Genome for Drug Resistance Testing	Federica Stefanelli, Genova
204	Exploring the relationship between HIV-DNA load and archived antiretroviral drug resistance in treated individuals with suppressed or low-level viremia	Daniele Armenia, Roma
211	HIV-1 Whole Genome Sequencing: comparative analysis of Illumina and Nanopore technologies	Federica Stefanelli, Genova
340	HIV-DNA Analysis in PLWH with a complex treatment history: correlation with immunological and virological parameters	Roberta Campagna, Roma
82	In vitro characterization of Peptidomimetic Proteolysis Targeting Chimera (PROTAC) as a Degradator of 3-Chymotrypsin-Like Protease (Mpro/3CLpro) against SARS-CoV-2	Mirko Giuseppe Litorri, Milano
107	INJECTION SITE PAIN AND CABOTEGRAVIR/RILPIVIRINE TROUGH PLASMA CONCENTRATION IN PEOPLE WITH HIV	Caterina Candela, Milano